Xponance Inc. Buys 989 Shares of Sotera Health (NASDAQ:SHC)

Xponance Inc. increased its position in Sotera Health (NASDAQ:SHC) by 6.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,495 shares of the company’s stock after acquiring an additional 989 shares during the quarter. Xponance Inc.’s holdings in Sotera Health were worth $239,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC raised its position in shares of Sotera Health by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company’s stock valued at $711,000 after buying an additional 1,047 shares during the last quarter. GAMMA Investing LLC grew its stake in Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock valued at $56,000 after acquiring an additional 1,121 shares in the last quarter. Blue Trust Inc. lifted its stake in Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock worth $25,000 after purchasing an additional 1,140 shares in the last quarter. True Wealth Design LLC bought a new position in shares of Sotera Health during the 3rd quarter valued at about $32,000. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Sotera Health by 17.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,839 shares of the company’s stock valued at $217,000 after purchasing an additional 2,340 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Down 0.3 %

Shares of SHC opened at $11.77 on Friday. The firm has a fifty day moving average price of $12.84 and a 200-day moving average price of $14.01. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The firm has a market capitalization of $3.34 billion, a P/E ratio of 47.08 and a beta of 1.92. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.08.

Analyst Ratings Changes

A number of research firms recently commented on SHC. The Goldman Sachs Group started coverage on Sotera Health in a research report on Friday, December 6th. They issued a “neutral” rating and a $14.00 target price on the stock. Barclays dropped their target price on Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.